Novartis wins EU approval for blood cancer therapy Kymriah
Novartis is investing 90 million Swiss francs ($90.4 million) in a new Swiss facility to produce Kymriah
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Pfizer’s tafamidis reduces risk of death by 30 %, reveals study
The data was presented at the European Society of Cardiology Congress in Munich
Making it future ready
On Teachers’ Day, experts comment on ways to improve pharmacy education in the country
Build excitement in the learning process | Dr B Suresh
From time immemorial medicinal plants have been the source of many new drugs and the discovery of new molecules. With the…
Need to re-engineer pharmacognosy science | Dr Swarnlata Saraf
The pharmacognosy branch of pharmaceutical sciences can remain in the pharmacy profession with re-engineering the contents…
The subject is essential for pharma science | Dr N Udupa
Pharmacognosy subject is an essential area for the development of pharmaceutical sciences. Along with pharmacology,…
Pharmacognosy as a branch needs to be looked upon as a vast area | Dr Madhu Chitkara
The first commercial pure natural product introduced for therapeutic use as pure compound was morphine from opium poppy plant…
We need to upgrade ourselves | Prof Raghuram Rao Akkinepally
How is NIPER, as a premier pharma education institute in India, encouraging adoption of industry best practices, providing…
Institutes need to create an ecosystem | Prof Navin Sheth
India Pharma Inc is on the brink of a huge transformation. What is the strategy shift that is needed in pharmacy education to…
We should aim for more research output | Dr N Udupa
What is the strategy shift that is needed in pharmacy education to accelerate the industry’s growth story?
The Indian pharma…